Autosomal Dominant Polycystic Kidney Disease market
Press Release

DelveInsight launched its new report on Autosomal Dominant Polycystic Kidney Disease – Market Insights, Epidemiology, and Market Forecast-2030.

DelveInsight’s “Autosomal Dominant Polycystic Kidney Disease Market” report delivers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

View report: https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disorder which causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations. Renal manifestations are produced by the progressive and continuous enlargement and proliferation of fluid-filled cysts, leading to enlargement of the kidney up to five times the normal volume in the years prior to the development of kidney failure. ADPKD may lead to development of end-stage renal disease (ESRD) and is the fourth most common renal disease requiring renal replacement therapy (RRT). The most common extra-renal manifestation is polycystic liver disease (PLD), which is more common in women than in men.

Key facts of the report:
1. Autosomal Dominant Polycystic Kidney Disease affects more than 600,000 Americans and 12.4 million people worldwide.
2. Autosomal Dominant Polycystic Kidney Disease prevalence is estimated to range from 1 in 400 to 1000 live births, with 5,000–6,000 new cases diagnosed each year.

Key benefits of the report:

  1. Autosomal Dominant Polycystic Kidney Disease market report covers a descriptive overview and comprehensive insight of the Autosomal Dominant Polycystic Kidney Disease epidemiology and Autosomal Dominant Polycystic Kidney Disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
    2. Autosomal Dominant Polycystic Kidney Disease market report provides insights on the current and emerging therapies.
    3. Autosomal Dominant Polycystic Kidney Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.
    4. Autosomal Dominant Polycystic Kidney Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Autosomal Dominant Polycystic Kidney Disease market.

“Autosomal Dominant Polycystic Kidney Disease prevalence increased with age and reached a peak value of 261 per million population in the age group of 55-59 years in Japan.”

Request for sample pages: https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market

The key players in Autosomal Dominant Polycystic Kidney Disease market are:
1. Kyowa Hakko Kirin
2. Palladio Biosciences
3. Sanofi
4. Reata Pharmaceuticals
5. Regulus Therapeutics

The launch of the emerging therapies is expected to significantly impact Autosomal Dominant Polycystic Kidney Disease treatment scenario in the upcoming years:-

Drugs covered:
1. Venglustat
2. Bardoxolone
3. Lixivaptan
4. RGLS4326

Table of contents:

  1. Report Introduction
    2. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance
    3. Autosomal Dominant Polycystic Kidney Disease Background and Overview
    4. Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population
    4.6. United States
    4.7. EU-5
    4.8. Assumptions and Rationale
    4.9. Germany
    4.10. France
    4.11. Italy
    4.12. Spain
    4.13. United Kingdom
    5. Autosomal Dominant Polycystic Kidney Disease Treatments & Medical Practices
    6. Autosomal Dominant Polycystic Kidney Disease Marketed Therapies
    6.1. Jynarque (tolvaptan): Otsuka Pharmaceuticals
    7. Autosomal Dominant Polycystic Kidney Disease Emerging Therapies
    8. Key Cross Competition
    8.1. Venglustat: Sanofi
    8.2. Lixivaptan: Palladio Biosciences
    8.3. Bardoxolone: Reata Pharmaceuticals
    8.4. XRx-008: XORTX Therapeutics
    8.5. RGLS4326: Regulus Therapeutics
    9. Autosomal Dominant Polycystic Kidney Disease Market Size
    10. 7MM Autosomal Dominant Polycystic Kidney Disease Country-Wise Market Analysis
    11. United States Market Size
    12. Germany Market Size
    13. France Market Size
    14. United Kingdom Market Size
    15. Spain Market Size
    16. Italy Market Size
    17. Japan Market Size
    18. Report Methodology
    19. DelveInsight Capabilities
    20. Disclaimer
    21. About DelveInsight

Download report: https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market

Related reports:

Autosomal Dominant Polycystic Kidney Disease – Epidemiology Forecast to 2030

Autosomal Dominant Polycystic Kidney Disease Pipeline Insight, 2020